Business Context and Reporting Period
This Form 8-K Current Report was filed by IRIDEX Corporation on May 21, 2019. The filing discloses the immediate appointment of David I. Bruce as President and Chief Executive Officer, succeeding William Moore. Mr. Bruce, 59, had previously served on the Board of Directors since April 2018.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation and governance changes.
Material Changes
The primary material change is the leadership transition at the CEO level. Additionally, the Board of Directors made the following committee adjustments effective May 21, 2019:
- Removed David I. Bruce from the Compensation and Audit Committees.
- Appointed Scott Shuda to the Compensation and Audit Committees.
- Designated Maria Sainz as Chair of the Compensation Committee.
- Replaced Sanford Fitch with Kenneth Ludlum as Chair of the Audit Committee.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new CEO under an Offer Letter dated May 17, 2019:
- Base Salary: $360,000 annually.
- Short-Term Incentive: Target annual bonus of up to 60% of base salary, contingent on corporate and individual objectives.
- Equity Grants:
- 270,000 stock options granted immediately, vesting 25% on the one-year anniversary and the remainder monthly thereafter.
- 400,000 additional stock options granted, vesting based on the achievement of specified stock price targets by December 31, 2023.
- Change in Control Severance: Entitles Mr. Bruce to 150% of annual base salary plus target bonus, full equity vesting acceleration, and up to 12 months of COBRA reimbursement if terminated without cause or resigning for good reason following a change in control.
The filing contains no forward-looking financial guidance or management commentary regarding business outlook.
Investor Verification Checklist
- Verify the terms of the Change in Control Severance Agreement, which is to be filed separately.
- Review the full text of the Offer Letter (Exhibit 10.1) for complete rights and obligations.
- Monitor the vesting schedule of the 400,000 performance-based stock options against future stock price targets.
- Assess the impact of the new CEO's background in medical device leadership on the company's strategic direction.